Literature DB >> 23105784

Evaluation of immunohistochemistry and enzyme linked immunosorbent assay for HER-2/neu expression in breast carcinoma.

Rani James1, K Thriveni, Girija Ramaswamy, Lakshmi Krishnamoorthy, Geetashree Mukherjee, P P Vijayalaxmi Deshmane, P P Bapsy.   

Abstract

HER-2 is overexpressed in approximately 20-30% of invasive Breast Cancer. ECD of the HER-2 protein is frequently cleaved and released into the circulation, where it can be detected by ELISA in up to 45% of patients with metastatic breast cancer. The objective of our study was to compare the current methods for the detection of HER-2 protein. Tissue HER-2 levels were studied in 100 breast cancer patients by IHC and compared with serum HER-2 levels by ELISA. IHC frequency was 29%. Serum HER-2 ECD was positive in 42% of patients. A statistically significant correlation was observed. HER-2 detected by IHC correlates significantly with serum HER-2 levels detected by ELISA. Thus, ELISA is a reliable and economical tool to assess the HER-2 status in tumors, when breast tissue sample is not available.

Entities:  

Keywords:  Breast cancer; ECD; ELISA; HER-2; IHC

Year:  2008        PMID: 23105784      PMCID: PMC3453142          DOI: 10.1007/s12291-008-0076-5

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  27 in total

1.  Is circulating HER-2 more than just a tumor marker?

Authors:  J Baselga
Journal:  Clin Cancer Res       Date:  2001-09       Impact factor: 12.531

2.  Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma.

Authors:  D Gancberg; A Di Leo; G Rouas; T Järvinen; A Verhest; J Isola; M J Piccart; D Larsimont
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

3.  Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.

Authors:  D F Hayes; H Yamauchi; G Broadwater; C T Cirrincione; S P Rodrigue; D A Berry; J Younger; L L Panasci; F Millard; D B Duggan; L Norton; I C Henderson
Journal:  Clin Cancer Res       Date:  2001-09       Impact factor: 12.531

4.  Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy.

Authors:  L N Harris; V Liotcheva; G Broadwater; M J Ramirez; P Maimonis; S Anderson; T Everett; D Harpole; M B Moore; D A Berry; D Rizzeri; J J Vredenburgh; R C Bentley
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

5.  Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy.

Authors:  N M Diaz
Journal:  Cancer Control       Date:  2001 Sep-Oct       Impact factor: 3.302

6.  Risk of breast cancer according to the status of HER-2/neu oncogene amplification.

Authors:  W Y Huang; B Newman; R C Millikan; K Conway; B S Hulka; M J Schell; E T Liu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-01       Impact factor: 4.254

7.  Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays.

Authors:  S Wang; M H Saboorian; E Frenkel; L Hynan; S T Gokaslan; R Ashfaq
Journal:  J Clin Pathol       Date:  2000-05       Impact factor: 3.411

8.  Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites.

Authors:  D Gancberg; A Di Leo; F Cardoso; G Rouas; M Pedrocchi; M Paesmans; A Verhest; C Bernard-Marty; M J Piccart; D Larsimont
Journal:  Ann Oncol       Date:  2002-07       Impact factor: 32.976

Review 9.  HER-2-targeted therapy: lessons learned and future directions.

Authors:  Rita Nahta; Francisco J Esteva
Journal:  Clin Cancer Res       Date:  2003-11-01       Impact factor: 12.531

10.  A murine monoclonal antibody that recognizes an extracellular domain of the human c-erbB-2 protooncogene product.

Authors:  T Masuko; K Sugahara; M Kozono; S Otsuki; T Akiyama; T Yamamoto; K Toyoshima; Y Hashimoto
Journal:  Jpn J Cancer Res       Date:  1989-01
View more
  2 in total

Review 1.  Challenges in the clinical utility of the serum test for HER2 ECD.

Authors:  Lian Lam; Nicholas McAndrew; Marla Yee; Ting Fu; Julia C Tchou; Hongtao Zhang
Journal:  Biochim Biophys Acta       Date:  2012-04-03

2.  Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience.

Authors:  Rashmi Patnayak; Amitabh Jena; Nandyala Rukmangadha; Amit Kumar Chowhan; K Sambasivaiah; Bobbit Venkatesh Phaneendra; Mandyam Kumaraswamy Reddy
Journal:  Indian J Med Paediatr Oncol       Date:  2015 Apr-Jun
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.